share_log

Scotiabank Initiates Coverage On EyePoint Pharmaceuticals With Sector Outperform Rating, Announces Price Target of $18

Benzinga ·  Oct 16, 2024 10:33  · Ratings

Scotiabank analyst Greg Harrison initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Sector Outperform rating and announces Price Target of $18.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment